
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care is poised for substantial growth, as indicated by its recently reported top-line revenue of $252.4 million, reflecting a year-over-year increase of 20.6%, which exceeded consensus expectations. The company’s product pipeline, particularly the launch of the Mobi pump and FDA clearance for Type 2 diabetes patients, positions it to capitalize on a significantly expanded market, with more than double the addressable population. Furthermore, high customer satisfaction is driving strong retention rates and consistent growth, underlining Tandem's potential to maintain double-digit revenue growth in the MedTech sector.
Bears say
Tandem Diabetes Care has faced significant operating losses since its inception, raising concerns about its ability to achieve sustained profitability. The company reported weaker-than-expected sales trends and provided underwhelming 2025 guidance, indicating potential challenges such as slower market expansion and competition that may hinder growth. Additionally, margins fell short of consensus expectations while uncertainties in reimbursement and geopolitical conditions further complicate future financial performance.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares